Aim immunotech announces publication of positive findings from a study evaluating ampligen® in the treatment of pancreatic cancer in the journal clinical cancer research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to tlr-3 activation through ampligen data demonstrate compelling evidence of the immune-stimulatory properties linked to tlr-3 activation through ampligen
AIM Ratings Summary
AIM Quant Ranking